Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Going Concern and Plan of Operations (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ (21,181,031)		$ (21,181,031)		$ (14,051,764)
Net loss	$ (2,154,625)	$ (2,611,828)	$ (7,129,267)	$ (7,176,723)	$ 10,200,000

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.